Two phase 3, long-term studies of esketamine nasal spray plus oral antidepressant in patients with treatment-resistant depression: Sustain-1 (randomized, withdrawal, double-blind, relapse prevention study) and sustain-2 (open-label, safety and efficacy study)

The requested reference [3c1707d671559dfddf9ed71be64c13312435c3fc] no longer exists in our database. It has been replaced by the current reference: [fde269c4f9d23309a7c8661b20db7ff5e6fcaa80]

Authors
Category Primary study
JournalAustralian and New Zealand Journal of Psychiatry
Year 2019
This article has no abstract
Epistemonikos ID: 6ffe185bad7a828ac9ee4be67d73bc79c8f83968
First added on: Feb 10, 2025